A 9-year-old girl with asthma is using a salbutamol inhaler daily and has peak expiratory flow rate 78% of best. The most appropriate next step is to start regular inhaled corticosteroid therapy. Which option describes the correct starting regimen?

Study for the Foundation Year Pharmacy – Clinical Practice Test. Prepare with detailed questions, step-by-step explanations, and test format insights. Enhance your readiness and confidence!

Multiple Choice

A 9-year-old girl with asthma is using a salbutamol inhaler daily and has peak expiratory flow rate 78% of best. The most appropriate next step is to start regular inhaled corticosteroid therapy. Which option describes the correct starting regimen?

Explanation:
The key point is that persistent asthma in a child who needs daily relief inhaler and shows reduced lung function requires regular anti-inflammatory therapy with an inhaled corticosteroid. Starting a low-dose ICS helps control the underlying airway inflammation, lowers the frequency of symptoms, and reduces the risk of exacerbations. Beclometasone 100 mcg per puff, taken as 1 puff twice daily, provides a straightforward, low-dose daily regimen that is appropriate as initial controller therapy in a 9-year-old. It delivers anti-inflammatory effect with relatively low systemic exposure and helps improve peak flow over time as control improves. The other options aren’t as suitable for starting maintenance. A higher-dose ICS given only once daily carries more exposure and may not maintain steady anti-inflammatory protection throughout the day. Montelukast can be used as an alternative or add-on in some cases, but guidelines favor initiating regular inhaled corticosteroid therapy first for persistent pediatric asthma. Relying on a short-acting beta-agonist alone does not address the inflammation driving asthma and would not constitute proper controller therapy.

The key point is that persistent asthma in a child who needs daily relief inhaler and shows reduced lung function requires regular anti-inflammatory therapy with an inhaled corticosteroid. Starting a low-dose ICS helps control the underlying airway inflammation, lowers the frequency of symptoms, and reduces the risk of exacerbations.

Beclometasone 100 mcg per puff, taken as 1 puff twice daily, provides a straightforward, low-dose daily regimen that is appropriate as initial controller therapy in a 9-year-old. It delivers anti-inflammatory effect with relatively low systemic exposure and helps improve peak flow over time as control improves.

The other options aren’t as suitable for starting maintenance. A higher-dose ICS given only once daily carries more exposure and may not maintain steady anti-inflammatory protection throughout the day. Montelukast can be used as an alternative or add-on in some cases, but guidelines favor initiating regular inhaled corticosteroid therapy first for persistent pediatric asthma. Relying on a short-acting beta-agonist alone does not address the inflammation driving asthma and would not constitute proper controller therapy.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy